CURRENT OHASHI LAB MEMBERS
ASSOCIATED RESEARCH LABS
Sacher Lab
ADRIAN G SACHER, MD, MMSc, FRCPC
Assistant Professor
Staff Oncologist
Clinician Investigator
FACULTY PAGE
Lab focus
Our work is centered on non-small cell lung cancer (NSCLC), with four major areas of investigation:
(i) Development of novel immunotherapeutics in NSCLC including immunmodulators, mRNA vaccines and adoptive cell therapy.
(ii) Characterizing the immune microenvironment of NSCLC and identification of novel therapeutic targets.
(iii) Evaluating the role of emerging immune cell subsets including mucosal-associated invariant T (MAIT) cells in modulating anti-tumor immunity and response to bacterial and endogenous metabolites.
(iv) Leveraging cfDNA, soluble biomarkers, and immunophenotyping to predict response and resistance to immunotherapy in solid tumors.
Assistant Professor
Staff Oncologist
Clinician Investigator
FACULTY PAGE
Lab focus
Our work is centered on non-small cell lung cancer (NSCLC), with four major areas of investigation:
(i) Development of novel immunotherapeutics in NSCLC including immunmodulators, mRNA vaccines and adoptive cell therapy.
(ii) Characterizing the immune microenvironment of NSCLC and identification of novel therapeutic targets.
(iii) Evaluating the role of emerging immune cell subsets including mucosal-associated invariant T (MAIT) cells in modulating anti-tumor immunity and response to bacterial and endogenous metabolites.
(iv) Leveraging cfDNA, soluble biomarkers, and immunophenotyping to predict response and resistance to immunotherapy in solid tumors.
Current Students
Saibil Lab
SAM SAIBIL, MD, PhD, FRCPC
Assistant Professor
Staff Oncologist
Clinician Investigator
FACULTY PAGE
Lab focus
The Saibil lab studies metabolic reprogramming of T cells for the improvement of adoptive cell therapy (ACT) for melanoma therapy.
Check out our recent review paper.
Assistant Professor
Staff Oncologist
Clinician Investigator
FACULTY PAGE
Lab focus
The Saibil lab studies metabolic reprogramming of T cells for the improvement of adoptive cell therapy (ACT) for melanoma therapy.
Check out our recent review paper.
Current students













